[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440108":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":41,"collaborators":7,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Nationwide Children's Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","NT3 blood draw","blood draw",[14],{"name":15,"affiliation":5,"role":16},"Zarife Sahenk, MD., PhD.","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Dawn Scott, RN","CONTACT","614722-2715","Dawn.Scott@nationwidechildrens.org",[24],{"facility":5,"status":7,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Columbus","Ohio","43205","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-82.99879,39.96118,{"lat":34,"lon":33},[37],{"name":38,"role":20,"phone":39,"phoneExt":7,"email":40},"Dawn Scott","(614)7222715","dawn.scott@nationwidechildrens.org",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Zarife Sahenk","Principal Investigator","100440108","nt-3-levels-and-function-in-individuals-with-cmt-100440108",false,"NCT05011006","NT-3 Levels and Function in Individuals With CMT","Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy","Inclusion Criteria:\n\n* Males or females from 7 years of age or older\n* Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG\u002Fnerve conduction studies.2\n* Perform assessments to the best of their ability with reliable results as deemed by the evaluator.\n* Ability to attend scheduled appointments\n* Ability to provide informed consent (or assent for ages 9-18)\n\nExclusion Criteria:\n\n* Current pregnancy per medical history\n* Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability","ALL","7 Years",{"count":55,"type":56},50,"ESTIMATED","OBSERVATIONAL","This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.",[60,61,62],"Charcot-Marie-Tooth Disease","Peripheral Neuropathy","Chronic Inflammatory Demyelinating Polyneuropathy",[64,65,66],"NT-3","CMT1A","Neuropathy","NOT_YET_RECRUITING","2025-06-18",{"date":70,"type":71},"2025-06-24","ACTUAL",{"date":73,"type":56},"2027-11-13",{"date":75,"type":56},"2030-06",{"name":43,"class":6},1]